WHC is still in active development. Read this to understand our approach.
depiction of GOWRRBABHQUJMX-UHFFFAOYSA-N.svg
tripsit

fasoracetam

Verificar en tripsit

psychonaut

Fasoracetam

Verificar en psychonaut

isomerdesign

Fasoracetam

Verificar en isomerdesign

drugmap

FASORACETAM

Verificar en drugmap

Data

InChI: InChI=1S/C10H16N2O2/c13-9-5-4-8(11-9)10(14)12-6-2-1-3-7-12/h8H,1-7H2,(H,11,13)

Sinónimos: MFCD00875708,AKOS006280726,A894820,(5R)-5-(piperidine-1-carbonyl) pyrrolidin-2-one,MDGN-001,NFC1 ANHYDROUS,2-Pyrrolidinone, 5-(1-piperidinylcarbonyl)-, (5R)-,NFC-1 ANHYDROUS,NS105,BS-49484,(+)-1-(((R)-5-Oxo-2-pyrrolidinyl)carbonyl)piperidine,LAM-105 ANHYDROUS,ZINC3779713,AC-31949,Fasoracetam ;aka NS-105 ;LAM-105),(r)-1-[(5-oxo-2-pyrrolidinyl)carbonyl]piperidine,DSSTox_GSID_48855,4-Methyl-6-trifluoromethylnicotinicacid,CHEMBL2106179,AEVI-001,NS 105 (pharmaceutical),110958-19-5,UNII-42O8UF5CJB,NCGC00182992-01,Q5436839,Tox21_113340,(R)-5-(piperidine-1-carbonyl)pyrrolidin-2-one,AEVI001,LAM 105,NS-105,CHEBI:31592,5-(Piperidine-1-carbonyl)pyrrolidin-2-one,LAM-105,(5R)-5-(1-piperidinylcarbonyl)-2-pyrrolidinone, (R)-5-(Piperidin-1-ylcarbonyl)pyrrolidin-2-one,5-Oxoprolinepiperidinamide,BCP16788,N-(5-Oxo-D-prolyl)piperidine,CAS-110958-19-5,DSSTox_CID_28781,NFC 1,(R)-1-((5-Oxo-2-pyrrolidinyl)carbonyl)piperidine,Fasoracetam,DTXSID9048855,EX-A736,NS 105, Fasoracetam,42O8UF5CJB,Piperidine, 1-((5-oxo-2-pyrrolidinyl)carbonyl)-, (R)-,LAM105 ANHYDROUS,Fasoracetam [INN],DSSTox_RID_83050,(5R)-5-(piperidine-1-carbonyl)pyrrolidin-2-one, NS-105, (R)-1-[(5-Oxo-2-pyrrolidinyl)carbonyl]piperidine,1-((5-Oxo-2-pyrrolidinyl)carbonyl)piperidine,SCHEMBL194770

Estimated data

Solubilidad: -1.016 (log(S) in mol/L prediction using SolTranNet)

Blood Brain Barrier Permeability: Yes (prediction using frontiersin.org)

Addictivity Prediction: 53.2% (prediction based on www.mdpi.com)

Similitudes

The following is a set of comparisons to understand the properties of this compound. This is still higly experimental and is still under active development. Please refer to our series of blog posts to fully understand our approach and its limitations. This information is for informational purposes only and should not be construed as medical advice.